The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.
Susan Halabi
Honoraria - Bayer; BN ImmunoTherapeutics
Research Funding - Sanofi
William Kevin Kelly
No relevant relationships to disclose
Haojin Zhou
No relevant relationships to disclose
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Dendreon; Janssen; Medivation; Sanofi
Honoraria - Dendreon; Pfizer; Sanofi
Research Funding - Active Biotech; Dendreon; Janssen; Medivation; Novartis; Pfizer; Sanofi
David Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Karim Fizazi
No relevant relationships to disclose
Nicole C Solomon
No relevant relationships to disclose
Ian Tannock
Research Funding - Sanofi
Daniel Peter Petrylak
Research Funding - Sanofi
Michael J. Morris
Consultant or Advisory Role - Janssen (U); Millennium
Research Funding - Bayer; Sanofi
Eric Jay Small
No relevant relationships to disclose